OCS OCULIS HOLDING AG

Oculis Publishes 2025 Consolidated Financial Statements

Oculis Publishes 2025 Consolidated Financial Statements

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now been filed with the SEC on form 20-F, are attached.

Attachments



EN
05/03/2026

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes 2025 Consolidated Financial Statements

Oculis Publishes 2025 Consolidated Financial Statements ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now been filed with the SEC on form 20-F, are attached. Attachments

2h / 16m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Participate in Upcoming Investor Conferences

Oculis to Participate in Upcoming Investor Conferences ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor conferences in March. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader i...

2h / 16m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Participate in Upcoming Investor Conferences

Oculis to Participate in Upcoming Investor Conferences ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor conferences in March. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader i...

2h / 16m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment

14h / 1m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Co...

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update ZUG, Switzerland, March 03, 2026 (GLOBE NEWSWIRE) -- Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity o...

March 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch